<DOC>
	<DOCNO>NCT00186277</DOCNO>
	<brief_summary>To combine oxaliplatin taxotere patient prior cisplatin therapy bladder cancer .</brief_summary>
	<brief_title>Phase II Study Oxaliplatin Taxotere Metastatic Bladder Cancer</brief_title>
	<detailed_description>To test combination oxaliplatin chemotherapy combination taxotere chemotherapy patient advanced bladder cancer fail one prior chemotherapy .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patient Population Type : Advanced Muscle Invasive Bladder Cancer Prior Therapy : One prior therapy advance disease Disease : Measurable disease ECOG Performance : 0,1 Indication : Histologically Proven Carcinoma bladder For female patient childbearing potential , neither pregnant breastfeeding , active contraception Allergies : No know allergy one study drug Patient Status : No CNS metastases No peripheral neuropathy &gt; grade1 No serious concomitant illness Fully recover prior therapy Informed Consent : Patient doctor sign informed consent Lower Age Limit : Lower age limit &gt; 18 Upper Age Limit : Upper Age Limit &lt; 70 ANC : ANC &gt; 1500/mm3 WBC &gt; 3000/mm3 Platelets : Platelets &gt; 100,000/mm3 Creatinine : Creatinine &lt; 1.8mg/dL Bilirubin : Bilirubin &lt; =2.0 x ULN SGPT : SGPT ( ALT ) &lt; =1.5 x ULN ( &lt; 4xULN liver metastasis present ) RBC : Hemoglobin &gt; 9.0g/dL Cardiovascular : No active congestive heart failure , uncontrolled angina , myocardial infarction within past 6 month Patients metastatic cancer urothelial tract ( TCC , Adenocarcinoma ) No prior exposure Oxaliplatin No cytotoxics radiation 4 week prior enrol protocol PT/PTT normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>